Extrachromosomal DNA drives molecular and clinical heterogeneity in hepatocellular carcinoma: a multi-omics analysis and prognostic model development

Key Points

• The aim is to explore molecular differences between ecDNA-negative and ecDNA-positive hepatocellular carcinoma and develop a prognostic gene signature.
• Conducted a multi-omics analysis between ecDNA-negative and ecDNA-positive HCC samples.
• Established a gene signature based on molecular data to predict patient outcomes.
• Compared clinical features associated with ecDNA presence.
• Identified significant molecular distinctions between ecDNA-negative and ecDNA-positive HCC cases.
• Developed a gene signature that predicts patient prognosis with validated accuracy.
• Demonstrated the role of ecDNA in contributing to tumor heterogeneity.